Newron Pharmaceuticals S.p.A. (NWRN.SW)
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.
11.94+0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+73.3%
The outlook
Newron Pharmaceuticals S.p.A. currently reads as leaning bearish based on below its 50- & 200-day averages, 21% of the way from its 52-week low to high, avg target +301% vs current price. This is a snapshot of current market data, not a forecast.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range21% of the way from its 52-week low to high
Price targetAvg target +301% vs current price
Analyst price target
~12-month · 4 analysts47.87average target+300.9% vs now
Now 11.94
Low 35.53High 73.98
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$248.4M
52-wk high
31.85
52-wk low
6.62
50-day avg
12.39
200-day avg
16.63
Trailing P/E
—